![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Telkom Indonesia Persero Tbk PT | TG:PTI | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.10 | 16.70 | 17.40 | 0.00 | 07:20:03 |
RNS Number:6299M Protherics PLC 23 June 2003 23 June 2003 Protherics plc Appointment of Directors Following the offer to acquire the whole of the issued and to be issued share capital of Enact Pharma plc ("Enact") being declared unconditional in all respects, Protherics plc ("Protherics"), announces the following appointments to the board with effect from 20 June 2003: *Dr Tony Atkinson as Chief Scientific Officer; and *Dr Mike Peagram as a non-executive director Dr Atkinson (age 58) has extensive experience within the biopharmaceutical industry having previously served as a director of Enact Pharma plc, Kymed G B Limited and Enzacta R&D Limited. Dr Peagram (age 60) previously served as Chairman of Enact Pharma plc. He is Deputy Chairman of Yule Catto and Co plc and was previously a Director of CRC Group plc and brings a wide range of business experience. Further to disclosure requirements of the UK Listing Authority, as specified in the Listing Rules, there are no further points under Rule 16.4(a) or 16.4(b) which require disclosure. Commenting on the appointment, Stuart Wallis, Chairman of Protherics, said: "We are delighted to welcome Tony and Mike to the Board of Protherics. Tony's extensive industry experience will help to guide our research and development programme, while Mike will add further strength to the Board in a non-executive capacity." - ENDS - For Further Information Please Contact: Protherics plc Tel: +44 (0) 20 7246 9950 Andrew Heath, CEO Maitland Consultancy Tel: +44 (0) 20 7379 5151 Brian Hudspith Notes to editors: Protherics PLC Protherics PLC was formed in September 1999 from the merger of Proteus International plc and Therapeutic Antibodies Inc. Protherics is an international biopharmaceutical company, whose platform technology is the development and production of immunotherapeutics. The Company's ordinary shares are listed on the Official List of the UK Listing Authority and are traded on the London Stock Exchange. An electronic version of this will be available at: www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END BOANKNKDKBKDAAB
1 Year Telkom Indonesia Persero... Chart |
1 Month Telkom Indonesia Persero... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions